Even though RBD mutation at amino-acid position 498 is not a missense mutation that presented in one or more of the VOCs, the RBD mutation such as Q498A has also been reported [51,52,53]

Even though RBD mutation at amino-acid position 498 is not a missense mutation that presented in one or more of the VOCs, the RBD mutation such as Q498A has also been reported [51,52,53]. == Physique 2. the binding affinity of SARS-CoV-2 variants with the receptor angiotensin transforming enzyme 2 (ACE2) and existing antibodies. Through the analysis, we found that the existing mutations have already covered almost all possible detrimental mutations that could result in an increase of transmissibility, and that a possible mutation in amino-acid position 498 of the RBD can potentially enhance its binding affinity. A new calculation method for the binding energies of proteinprotein complexes is usually proposed based on the entropyenthalpy compensation rule. All known structures of RBDantibody complexes and the RBDACE2 complex comply with the entropyenthalpy compensation rule in providing the driving pressure behind the spontaneous proteinprotein docking. The variant-induced risk of breakthrough infections in vaccinated people is usually attributed to the L452R mutations reduction of the binding affinity of many antibodies. Mutations reversing the hydrophobic or hydrophilic overall performance of residues in the spike RBD potentially cause breakthrough infections of coronaviruses due to the changes in geometric complementarity in the entropyenthalpy compensations between antibodies and the virus at the binding sites. Keywords:SARS-CoV-2, variants, RBD, mutations, antibody == 1. Introduction == The coronavirus disease 2019 (COVID-19) has spread worldwide, with more than 230 2”-O-Galloylhyperin million confirmed cases, and has led to an ongoing pandemic. In response to this once-in-a-century, sustained, worldwide pandemic, unprecedented amounts of funds and manpower have been invested to develop vaccines against the disease by governments, corporations, university research groups, and international health businesses [1]. Thanks to the rapid development of vaccine technology in recent years [1], six vaccines approved by the World Health Business (WHO) for emergency use have been massively employed in global vaccination programs to immunize the population against COVID-19 contamination, while dozens of other vaccine candidates are being prepared for Phase III trials. By September 2020, about 20 countries experienced vaccinated over 70% of their populations, and the best vaccination rates in the world are not only dominated by small countries. Almost all existing vaccines have been developed based on the initial SARS-CoV-2 strain that was originally recognized in China, or around the genetic sequence data that enable vaccine-induced antibodies to stop the 2”-O-Galloylhyperin original SARS-CoV-2 strain from distributing in a fully vaccinated population. Indeed, the original SARS-CoV-2 strain is usually disappearing in countries with the best vaccination rates. However, the SARS-CoV-2 variants have almost replaced the initial SARS-CoV-2 strain and are 2”-O-Galloylhyperin distributing in these countries, according to GISAID data [2,3,4]. At present, in Japan, the proportion of cases infected with the Delta variant is usually close to 65%, and it is constantly increasing; in Singapore, contamination by the Delta strain has accounted for about 95% of all infections in the region; in Israel, about 90% of new infections are likely caused by the Delta variant; in the United States, the Delta computer virus infection rate has reached 83% among the newly infected people tested; in the United Kingdom, the proportion of Delta contamination samples in the last four weeks before the writing of this paper was as high as 99%. Four Variants of Concern (VOCs) and five Variants of Interest (VOIs) are recognized by the WHO. The increased transmissibility and breakthrough infections caused by the VOCs are believed to be due to mutations in the structure of the spike (S) proteins [5]. There have been a number of missense mutations observed in the receptor-binding domain name (RBD) of the SARS-CoV-2 S protein, which have offered in one or more of the VOCs, including the N440K, G446V, L452R, Y453F, E484Q, F490S, N501Y, N501S, E484K, and K417N [5,6,7,8], most of 2”-O-Galloylhyperin which are located at the RBDACE2 interface. Understanding the physical mechanism responsible for the mutation-induced changes in the RBDs binding affinity with the receptor angiotensin transforming enzyme 2 (ACE2) and antibodies is the urgent challenge in the development of preventive steps, vaccines, and therapeutic antibodies against the COVID-19 pandemic [8,9,10,11,12,13,14,15]. A key question is usually whether existing COVID-19 vaccine-induced antibodies can protect against the infection 2”-O-Galloylhyperin or diseases from these SARS-CoV-2 variants. Most vaccine-induced antibodies neutralize the SARS-CoV-2 variants MAP2K2 via the proteinprotein docking between the CoV S RBD and the antibodies [1]. The key to vaccine-induced immunity is the ability of the induced antibodies to specifically bind to the SARS-CoV-2 with a strong binding affinity. The complex.